Growth Factor Changes in Cerebrospinal Fluid of Children with Mental Retardation before and after Neural Precursor Cell Transplantation

CNS Neurol Disord Drug Targets. 2018;17(2):98-105. doi: 10.2174/1871527317666180411102337.

Abstract

Objective: To investigate growth factor changes in cerebrospinal fluid (CSF) of children with mental retardation (MR) before and after neural precursor cell transplantation (NPCT), in an attempt to provide experimental support for the clinical treatment of MR with NPCT.

Methods: The study comprised of 28 MR children who received twice NPCT in our hospital. CSF was collected at both times of NPCT to assess growth factors by ELISA. In addition, the content of insulinlike growth factor 1 (IGF-1) in CSF was assayed to determine possible correlations between IGF-1 changes and the short-term therapeutic effect of NPCT.

Results: Of all the growth factors detected in CSF, only IGF-1 was increased significantly after NPCT (P<0.05). Fifteen of the twenty-eight MR children achieved short-term therapeutic efficacy, whereby the content of IGF-1 after NPCT was significantly higher than that before NPCT (P<0.05). There was no difference in IGF-1 content before and after NPCT in the remaining 13 MR children without shortterm therapeutic effect (P=0.657). There was a significant difference in IGF-change between the two groups of patients (P<0.05).

Conclusion: IGF-1 may be one of the mechanisms contributing to the therapeutic effect of NPCT.

Keywords: Mental retardation; growth factors; insulin-like growth factor 1; intellectual disability; neural precursor cell; transplantation..

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Insulin-Like Growth Factor I / cerebrospinal fluid*
  • Intellectual Disability / cerebrospinal fluid*
  • Intellectual Disability / surgery
  • Intercellular Signaling Peptides and Proteins / cerebrospinal fluid
  • Male
  • Neural Stem Cells / transplantation*
  • Time Factors
  • Treatment Outcome

Substances

  • IGF1 protein, human
  • Intercellular Signaling Peptides and Proteins
  • Insulin-Like Growth Factor I